12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Firdapse amifampridine 3: Phase III ongoing

Catalyst said an IDMC recommended continuation of a double-blind, placebo-controlled, international Phase III trial of Firdapse based on a review of safety and clinical data. The trial is evaluating Firdapse given 3-4 times daily in about 30 patients, who will receive a total daily dose of 30-80 mg,...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >